Warning letters, 483s, Recalls, Import Alerts, Audit observations
USFDA inspection of Cipla, Patalganga site manufacturing APIs and Tablets resulted in USFDA 483 with
The DRL site was inspected by USFDA (Investigators Saleem A Akhtar & Pratik S Upadhyay)
Natco Pharma (india) Kothur facility was inspected by USFDA (Investigators Pratik S. Upadhyay and Saleem
Natco Pharma (india) Kothur facility was inspected by USFDA in October 2023. The site (FEI
Spectrum Laboratories Inc, New Jersey, USA (FEI 2246824) was inspected by FDA investigators Sayyem H
Related Links Warning letter Intas Warning letter Centaur Warning letter Medgel Warning letter Baxter Intas
IPCA Dhar facility was inspected by USFDA in June 2023. The site (FEI 3007574780) was
FDA published the USFDA483 issued to Intas site (FEI 3003157498) in Ahmedabad, India after inspection
IPCA Ratlam (India) was issued USFDA 483 with 11 observations after inspection in June 2023
